Publications by authors named "Prudence Ive"

Claim this Profile
L
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis.
Seth C Inzaule, Stefanie Kroeze, Cissy M Kityo, Margaret Siwale, Sulaimon Akanmu, Prudence Ive

AIDS· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers.
Anabela C P Picton, Maria Paximadis, Gemma W Koor, Avani Bharuthram, Sharon Shalekoff, Prudence Ive

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Michelle A Kendall, Umesh Lalloo, Courtney V Fletcher, Xingye Wu, Anthony T Podany, Prudence Ive

Clin Infect Dis· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Giant bacillary angiomatosis.
Jeremy Nel, Prudence Ive, Carolina Nel

South Afr J HIV Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious disease consultations at a South African academic hospital: A 6-month assessment of inpatient consultations.
Lauren Richards, David C Spencer, Jeremy S Nel, Prudence Ive

S Afr J Infect Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
Seth C Inzaule, Silvia Bertagnolio, Cissy M Kityo, Margaret Siwale, Sulaimon Akanmu, Prudence Ive

AIDS· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update.
Nelesh P Govender, Graeme Meintjes, Phetho Mangena, Jeremy Nel, Samantha Potgieter, Prudence Ive

South Afr J HIV Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance.
Seth C Inzaule, Cissy M Kityo, Margaret Siwale, Alani Sulaimon Akanmu, Maureen Wellington, Prudence Ive

Sci Rep· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management and outcomes of Staphylococcus aureus bacteraemia at a South African referral hospital: A prospective observational study.
Nicola Steinhaus, Mohammed Al-Talib, Prudence Ive, Tom Boyles, Colleen Bamford

Int J Infect Dis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Stefanie Kroeze, Pascale Ondoa, Cissy M Kityo, Margaret Siwale, Sulaimon Akanmu, Prudence Ive

AIDS· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.
Julia K Rohr, Prudence Ive, Charles Robert Horsburgh, Rebecca Berhanu, Christopher J Hoffmann

J Acquir Immune Defic Syndr· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
Denise Evans, Kamban Hirasen, Rebecca Berhanu, Given Malete, Prudence Ive

AIDS Res Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Gupta-Wright et al.
Jeremy Stephen Nel, Prudence Ive, Christopher Kirk Lippincott

Clin Infect Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review.
Jeremy S Nel, Christopher K Lippincott, Rebecca Berhanu, David C Spencer, Ian M Sanne, Prudence Ive

Clin Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells.
Kapil K Saharia, Constantinos Petrovas, Sara Ferrando-Martinez, Manuel Leal, Rafael Luque, Prudence Ive

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
Julia K Rohr, Prudence Ive, C Robert Horsburgh, Rebecca Berhanu, Kate Shearer

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
Matthew P Fox, Rebecca Berhanu, Kim Steegen, Cindy Firnhaber, Prudence Ive

Trop Med Int Health· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa.
Julia K Rohr, Prudence Ive, C Robert Horsburgh, Rebecca Berhanu, Kate Shearer

J Int AIDS Soc· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.
Rodolphe Thiébaut, Ana Jarne, Jean-Pierre Routy, Irini Sereti, Margaret Fischl, Prudence Ive

Clin Infect Dis· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Rodney Dawson, Andreas H Diacon, Daniel Everitt, Christo van Niekerk, Peter R Donald, Prudence Ive

Lancet· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection.
Noor Dawany, Louise C Showe, Andrew V Kossenkov, Celia Chang, Prudence Ive

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study.
John A Crump, Xingye Wu, Michelle A Kendall, Prudence D Ive, Johnstone J Kumwenda

BMC Infect Dis· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.
Prudence Ive, William MacLeod, Nompumelelo Mkumla, Catherine Orrell, Ute Jentsch

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
David A Cooper, Jayvant Heera, Prudence Ive, Mariette Botes, Edwin Dejesus

AIDS· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
Alana T Brennan, Mhairi Maskew, Prudence Ive, Kate Shearer, Lawrence Long

J Int AIDS Soc· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis